检验医学与临床
檢驗醫學與臨床
검험의학여림상
JOURNAL OF LABORATORY MEDICINE AND CLINICAL SCIENCES
2013年
19期
2497-2498,2502
,共3页
禹立霞%谢丽%陈红%魏嘉%刘宝瑞
禹立霞%謝麗%陳紅%魏嘉%劉寶瑞
우립하%사려%진홍%위가%류보서
c-Kit%胃癌%预后
c-Kit%胃癌%預後
c-Kit%위암%예후
c-Kit%gastric cancer%prognosis
目的研究进展期胃癌组织c-Kit表达及与相关指标和预后的关系,以探讨c-Kit能否作为胃癌分子靶向药物治疗靶点。方法采用免疫组化法研究了69例进展期胃癌组织标本的c-Kit表达及与MDR1和SSTR2的相关性,并对患者进行总生存期随访。结果进展期胃癌组织c-Kit阳性表达率为24.6%。c-Kit表达与患者性别、年龄、分期、分化及脉管和神经侵犯均无相关性。肿瘤组织c-Kit表达与MDR1(P=0.049)和SSTR2(P=0.013)表达有相关性。c-Kit表达阴性患者中位总生存期为13.8个月(95%CI11.8~15.8个月),c-Kit表达阳性患者中位总生存期为12.5个月(95%CI9.58~15.42个月,P=0.049),两者差异具有统计学意义。ⅢA期病例c-Kit表达阴性患者中位总生存期为26.1个月(95%CI15.36~36.84个月),c-Kit表达阳性患者中位总生存期仅为12.5个月(95%CI7.51~17.49个月,P=0.04)。结论c-Kit可能是胃癌靶向酪氨酸激酶抑制剂使用靶点,但其相关机制有待体内外研究证实。
目的研究進展期胃癌組織c-Kit錶達及與相關指標和預後的關繫,以探討c-Kit能否作為胃癌分子靶嚮藥物治療靶點。方法採用免疫組化法研究瞭69例進展期胃癌組織標本的c-Kit錶達及與MDR1和SSTR2的相關性,併對患者進行總生存期隨訪。結果進展期胃癌組織c-Kit暘性錶達率為24.6%。c-Kit錶達與患者性彆、年齡、分期、分化及脈管和神經侵犯均無相關性。腫瘤組織c-Kit錶達與MDR1(P=0.049)和SSTR2(P=0.013)錶達有相關性。c-Kit錶達陰性患者中位總生存期為13.8箇月(95%CI11.8~15.8箇月),c-Kit錶達暘性患者中位總生存期為12.5箇月(95%CI9.58~15.42箇月,P=0.049),兩者差異具有統計學意義。ⅢA期病例c-Kit錶達陰性患者中位總生存期為26.1箇月(95%CI15.36~36.84箇月),c-Kit錶達暘性患者中位總生存期僅為12.5箇月(95%CI7.51~17.49箇月,P=0.04)。結論c-Kit可能是胃癌靶嚮酪氨痠激酶抑製劑使用靶點,但其相關機製有待體內外研究證實。
목적연구진전기위암조직c-Kit표체급여상관지표화예후적관계,이탐토c-Kit능부작위위암분자파향약물치료파점。방법채용면역조화법연구료69례진전기위암조직표본적c-Kit표체급여MDR1화SSTR2적상관성,병대환자진행총생존기수방。결과진전기위암조직c-Kit양성표체솔위24.6%。c-Kit표체여환자성별、년령、분기、분화급맥관화신경침범균무상관성。종류조직c-Kit표체여MDR1(P=0.049)화SSTR2(P=0.013)표체유상관성。c-Kit표체음성환자중위총생존기위13.8개월(95%CI11.8~15.8개월),c-Kit표체양성환자중위총생존기위12.5개월(95%CI9.58~15.42개월,P=0.049),량자차이구유통계학의의。ⅢA기병례c-Kit표체음성환자중위총생존기위26.1개월(95%CI15.36~36.84개월),c-Kit표체양성환자중위총생존기부위12.5개월(95%CI7.51~17.49개월,P=0.04)。결론c-Kit가능시위암파향락안산격매억제제사용파점,단기상관궤제유대체내외연구증실。
Objective To explore the relationship between c-Kit expression and prognosis of advanced gastric cancer .Methods c-Kit expression was detected in tissue samples from 69 cases of advanced gastric cancer by using immunochemistry ,and its relationship with DMR1 and SSTR2 was analyzed .Survival data of all patients were ana-lyzed by follow-up .Results The positive rate of c-Kit expression was 24 .6% .c-Kit expression was not related to gender ,age ,stage ,histological differentiation ,and nerves and vessels involvement ,but was related to MDR1 ( P=0 .049) and SSTR2 (P=0 .013) expression .The median overall survival of c-Kit negative patients was 13 .8 months (95% CI :11 .8-15 .8 months) ,while the median overall servival was 12 .5 months (95% CI:9 .58-15 .42 months) in c-Kit positive patients ,and the difference between the two groups was significant (P=0 .049) .The median overall servival of c-Kit negative and positive patients at stage ⅢA were 26 .1 months (95% CI:15 .36-36 .84 months) and 12 .5 months (95% CI:7 .51-17 .49 months) ,and the difference was significant (P=0 .04) .Conclusion c-Kit ex-pression might be related to survival of patients with advanced gastric cancer and could be a potential therapeutic tar-get ,which should be confirmed by further investigation .